rev5901a（101910241freebase）

REV 5901 is a competitive and orally effective leukotriene receptor antagonist (Ki of 0.7 μM) and a 5-lipoxygenase inhibitor, suitable for research on asthma involving leukotriene release [1] [2].

REV 5901A (REV 5901 HCl) is an orally active leukotriene receptor antagonist and 5-lipoxygenase inhibitor with antimicrobial activity that attenuates colon cancer growth in mice.REV 5901A has been used in studies of asthma and myocardial infarction. REV 5901A is used to study asthma and myocardial infarction.